A new subgroup analysis across the MONALEESA phase III program found that patients with visceral metastases who were treated with Kisqali (ribociclib) plus endocrine therapy in the first-line setting achieved a median OS of 62.7 months compared to 52.1 months for those treated with endocrine therapy alone.
Researchers at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences have been awarded five grants from NCI in 2024, totaling $4.6 million.
